Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (91324)	4/3/2000 2:15:00 PM
From: Jenna	Respond to of 120523

KING is up sharply, ADRX won't be far behind. ALKS has some good drugs in its pipeline and deals with LLY and Glaxo Welcome and DNA. Be responsible and don't just buy stocks because they are up today, buy if they are stocks with strong technical and fundmental rank, correcting and showing signs of recovery already. Do your own DD on stocks like SPOT, ADRX, PWAV, AMAT and ALKS.. Don't rely on tips that are not backed up by technical facts. Nothing is guaranteed, but at least to be well informed you have a good head start in picking leaders that are and will rebound. February 8: Drug delivery technologies developer Alkermes (Nasdaq: ALKS) jumped $16 1/2 to $111 after signing an agreement with drug maker Eli Lilly (NYSE: LLY) to develop an inhaled version of a human growth hormone using Alkermes' AIR technology. Under the deal, Alkermes will receive certain up-front fees, funding for research, and milestone payments. February 8-- Alkermes (ALKS) earned an increase in its price target today from PaineWebber analyst Elise Wang, who lifted the figure to $115 from $90, on the company's announcement of a pulmonary drug delivery technology licensing deal with Eli Lilly (LLY). Wang noted that "buy"-rated Alkermes has now forged relationships with the dominant players in the area of human growth hormone, having already inked an agreement with Genentech (DNA) for the sustained injectable formulation. The analyst said she believes that the most recent news is the third of five major collaborative announcements likely to be made this year, reiterating that Alkermes is one of her top stock picks among mid-cap biotech names with an advancing pipeline.